
Tourmaline Bio Inc
NASDAQ:TRML

Fundamental Analysis


Revenue & Expenses Breakdown
Tourmaline Bio Inc
Balance Sheet Decomposition
Tourmaline Bio Inc
Current Assets | 268.8m |
Cash & Short-Term Investments | 258.3m |
Other Current Assets | 10.5m |
Non-Current Assets | 40.2m |
Long-Term Investments | 36.6m |
PP&E | 267k |
Other Non-Current Assets | 3.3m |
Free Cash Flow Analysis
Tourmaline Bio Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Tourmaline Bio Inc
Revenue
|
0
USD
|
Operating Expenses
|
-89.7m
USD
|
Operating Income
|
-89.7m
USD
|
Other Expenses
|
16.5m
USD
|
Net Income
|
-73.2m
USD
|
TRML Profitability Score
Profitability Due Diligence
Tourmaline Bio Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

Score
Tourmaline Bio Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
TRML Solvency Score
Solvency Due Diligence
Tourmaline Bio Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Score
Tourmaline Bio Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TRML Price Targets Summary
Tourmaline Bio Inc
According to Wall Street analysts, the average 1-year price target for
TRML
is 54.63 USD
with a low forecast of 35.35 USD and a high forecast of 68.25 USD.
Dividends
Current shareholder yield for TRML is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?